Highlights of the Study
• Propofol and inhalation anesthetic agent can differently influence postoperative recurrence of hepatocellular carcinoma in a clinical setting.
• Postoperative two-year recurrence rate of hepatocellular carcinoma decreased when propofol was used as the main anesthetic agent.
• Propofol should be considered as an optimal anesthetic agent for patients with early stage hepatocellular carcinoma undergoing hepatic resection surgery. Hepatocellular carcinoma (HCC) is a solid type of cancer that has high recurrence and mortality rates [1] . Although locoregional treatments such as radiofrequency tumor ablation (RFA) and transarterial chemoembolization (TACE) can be applied, surgical resection or liver transplantation is the ultimate curative option for patients with early stage HCC [1, 2] . Nevertheless, the postoperative recurrence rate of HCC has previously been determined to be about 50% in two years [3, 4] , and several characteristics of HCC, such as tumor differentiation, tumor size and number and vascular invasion are risk factors for recurrence [3, 5] . In addition, nuclear factor-κB (NF-κB), natural killer (NK) cells, and several interleukins (IL) have been reported to be linked with the progression or recurrence of HCC [6, 7] .
Propofol and inhalation anesthetic agents, which are widely used anesthetic agents, function quite differently. Inhalation anesthetic agents decrease the activity of NK cells, while propofol does not suppress NK cell activity [8] . Moreover, propofol reduces the level of NF-κB, tumor necrosis factor (TNF)-α, IL-1β and IL-6, thus providing antioxidative and anti-inflammatory effects [9, 10] . Additionally, propofol has been shown to inhibit the migration and invasion of human cancer cells [11, 12] . Previous studies reported better outcome in HCC patients, when propofol was used for sedation or general anesthesia [13, 14] .
In this study, patients with early or intermediate-stage HCC were enrolled and a retrospective investigation was performed to evaluate the difference in the recurrence rate after hepatectomy for HCC according to the main anesthetic agents used, propofol or inhalation anesthetic agent. 
Subjects and Methods

General Anesthesia
General anesthesia was usually performed in the following manner. Midazolam was given to the patients commonly at the preoperative holding area. General anesthesia was induced under routine monitoring, which included electrocardiogram, invasive arterial pressure measurement and pulse oximetry. Three anesthesiologists had chosen an inhalation anesthetic agent, and the other two anesthesiologists had performed total intravenous anesthesia during anesthesia maintenance for laparoscopic hepatic resection.
When the inhalation anesthetic agent was chosen as the main anesthetic agent, propofol, rocuronium, and remifentanil were given only for initial sedation, neuromuscular block, and pain control, respectively. When total intravenous anesthesia was planned, propofol and remifentanil were administered via the target-controlled infusion method, and rocuronium was given intermittently.
Assessment of Postoperative HCC Recurrence
Postoperative HCC recurrence was evaluated for 24 months postoperatively.
Postoperative serial liver computed tomography (CT) was evaluated to judge the recurrence of HCC at an interval of every 3 -6 months. All liver CT scans were finally evaluated by certified radiologists. When HCC recurrence was observed in the liver CT, A c c e p t e d m a n u s c r i p t the time to recurrence after hepatic resection was recorded together.
Other Outcome Variables
Various factors that could influence the recurrence of HCC were evaluated as follows: (1) Child-Pugh score and BCLC staging classification (2) USA) was used for all analyses and p ≤0.05 was considered statistically significant.
Results
The following cases were excluded: patients who had HCC recurrence or metastasis to other organs when undergoing the operation, diagnosis other than HCC on the postoperative pathology, and intraoperative conversion from laparoscopic procedure to laparotomy. Finally, 259 patients were enrolled in this study for the analysis; 121 Table 1 .
The Kaplan-Meier curve of 24-month PFS according to the main anesthetic agent is shown in Figure 2 . HCC recurred less in the propofol group than in the inhalation group (p = 0.046), and the mean time to recurrence was 20.8 months (95% CI, 19.7-22.0) and
19.1 months (95% CI, 17.8-20.4) in the propofol and the inhalation group, respectively.
The overall 24-month PFS rates after surgery were 77.7% and 65.2% in the propofol and the inhalation group, respectively (p = 0.038). The HCC recurrence according to the main anesthetic agent and other variables was compared separately in a univariable and subsequently in a multivariable Cox proportional regression model. The propofol group showed significantly decreased recurrence rates than did the inhalation group (hazard ratio, 0.66; 95% CI, 0.42-1.05; p = 0.016). The multivariable Cox proportional regression model also presented results similar to those exhibited by the propofol group, which significantly decreased recurrence rates (hazard ratio, 0.57; 95% CI, 0.47-0.69; p = 0.029) compared with the inhalation group (Table 2 ). In addition, other variables that significantly increased the 24-month recurrence rate were the microvascular invasion and higher TNM stage in the multivariable Cox proportional regression model.
Discussion
This retrospective study showed that HCC patients with BCLC stage 0, A, or B had less postoperative recurrence when propofol was used as the main anesthetic agent compared to the use of inhalation anesthetic agent.
HCC is an inflammation-related cancer, and several risk factors for recurrence after surgical resection have been established: larger tumor size, multinodularity, worse A c c e p t e d m a n u s c r i p t differentiation, microvascular invasion, liver disease stage, age, and sex [3, 5] . In addition to these well-known pathological risk factors, it has recently been revealed that several molecular pathways with mediators such as IL-6, NF-κB, NK cells, TNF-α, and signal transducer and activator of transcription 3 are related to hepatocyte regeneration and development of HCC [6, 7] .
Previous studies have reported results similar to those of the present study. When propofol was used for sedation or general anesthesia, better survival was observed in HCC patients [13, 14] . In the present study, only patients with primary HCC of BCLC stage 0, A, or B were enrolled, and the surgical procedure was limited to laparoscopic hepatic resection in order to recruit the early-or intermediate-stage HCC, limit the basal characteristics to specific conditions, and reduce confounding factors as much as possible.
As such, the characteristics and risk factors of HCC as described above seem to be comparable between the two groups. Accordingly, other important risk factors for HCC recurrence such as macro-vascular invasion to the hepatic artery, hepatic vein, or portal vein [3, 5] were not observed in any patient. Moreover, all laparoscopic hepatic resections resulted in R0 resection, and no patient underwent postoperative adjuvant therapy in this study population. Our results may provide further reinforcing evidence regarding the nonanesthetic advantage of propofol in early-or intermediate-stage HCC patients.
Previous studies have reported that propofol has anti-tumor, anti-inflammatory and anti-oxidative effects in addition to its anesthetic properties [15] . On the contrary, inhalation anesthetics were reported to have immunosuppressive effects, although this remains a controversial issue [16] .
Propofol has been reported to decrease the viability, proliferation and invasion of . IL-6 knockout mice presented less hepatocarcinogenesis [27] , which corresponded with the elevated IL-6 levels in HCC patients [28] . Therapeutic levels of propofol has been shown to reduce the biosynthesis of several proinflammatory cytokines, such as TNF-α, IL-6, and IL-1β in activated macrophages [10] . However, each inhalation anesthetic agent seems to have varied complex effects on pro-or antiinflammatory cytokines [16] . Besides, hypoxia-inducible factor-1α (HIF-1α) has been known to be correlated with tumor development and expressed in various kinds of human tumor cells [29] , A major limitation of this study is that the duration of observation for HCC A c c e p t e d m a n u s c r i p t recurrence was limited to two years postoperatively; hence, we were unable to verify the long-term prognosis. However, it has previously been established that early recurrence of HCC has mostly occurred within one to two years of resection [4] . Another study with a larger group of patients, including cases with higher BCLC stages, showed similar results on long-term follow up [14] . Second, the recurrence of HCC was evaluated only by CT in the present study. However, other examinations such as positron emission tomography-CT or magnetic resonance imaging could be used to detect the postoperative recurrence of HCC [5] .
Conclusions
Postoperative two-year recurrence rate of early-and intermediate stage HCC Data were missing for the following variables: γ-GT (missing in 9 cases), PIVKA-II (missing in 80 cases), α-fetoprotein (missing in 4 cases), ICG test (missing in 30 cases), grade of differentiation, capsular infiltration, and microvascular invasion (missing in 11 cases, respectively). 
